Abstract:OBJECTIVEHepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Hepatic arterial chemoembolization transcatheter (TACE) is one of the main treatment methods for liver cancer. However, the long-term therapeutic effect of HCC after TACE is still unsatisfactory, postoperative recurrence and metastasis rate is still very high. Furthermore, TACE operation due to liver cancer tissue ischemia and hypoxia will lead to up-regulation of vascular endothelial growth factor (VEGF) expression. In the current study, we investigated the effects of suppressed VEGF on HCC and its molecular mechanism provided a basis for targeting angiogenesis.MATERIALS AND METHODSWe established rabbits primary HCC model by in situ embedding the VX2 subcutaneous transplantation tumor. Conventional Seldinger femoral artery and hepatic artery catheterization method were used to select the catheter over the tumor-bearing hepatic artery. The different groups were divided into TACE operation, and the experimental group was performed with the VEGF-siRNA molecular preparation in the catheter. 64-slice spiral CT were used to perfusion imaging of liver cancer model before and after TACE operation. We further assessed the efficiency of VEGF silencing and its influence on VX2 cells. The expression of VEGF mRNA and protein were detected by RT-PCR and Western blotting, respectively. Intratumoral microvessel density (MVD), VEGF and CD34 were evaluated by immunohistochemistry. We detected the cell apoptotic by immunofluorescence and flow cytometry.RESULTSOur findings indicated that VEGF-siRNA-2# could effectively suppress the expression of VEGF expression, inhibited the proliferation capability and promoted apoptosis of VX2 cells in vitro. Silencing of VEGF expression also suppress HCC tumor growth and reduce HCC angiogenesis in rabbits primary HCC model in vivo. Furthermore, We found that phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) activation were considerably reduced while inhibition VEGF expression in VX2 cells.CONCLUSIONSOur data demonstrated that VEGF silencing could suppress cells proliferation, promote cells apoptosis and reduce HCC angiogenesis through inactivation of VEGF/PI3K/AKT signaling pathway.

Silymarin Suppresses Proliferation of Human Hepatocellular Carcinoma Cells under Hypoxia Through Downregulation of the HIF-1α/VEGF Pathway.

Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer

Effect of Silymarin on Expression of micro-RNA-21 and Matrix Metalloproteinase (MMP) 2 and 9 and Tissue Inhibitors of Matrix Metalloproteinase (TIMP) 1 and 2 in Hepatocellular Carcinoma Cell Line (HepG2)

Silymarin Suppressed Lung Cancer Growth in Mice Via Inhibiting Myeloid-Derived Suppressor Cells.

Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice

Inhibition of SIRT1 Signaling Sensitizes the Antitumor Activity of Silybin Against Human Lung Adenocarcinoma Cells in Vitro and in Vivo.

Multitargeting and Antimetastatic Potentials of Silibinin in Human HepG-2 and PLC/PRF/5 Hepatoma Cells

Antiproliferative and Antitelomerase Effects of Silymarin on Human Colorectal and Hepatocellular Carcinoma Cells

The anti-lung cancer mechanisms of Silymarin via inhibiting myeloid-derived suppressor cells

Resveratrol Enhances Anticancer Effects of Silybin on HepG2 Cells and H22 Tumor-bearing Mice via Inducing G2/M Phase Arrest and Increasing Bax/Bcl-2 Ratio

Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis

Flavonoid Group of Smilax glabra Roxb. Regulates the Anti-Tumor Immune Response Through the STAT3/HIF-1 Signaling Pathway

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Sanshimao formula inhibits the hypoxia-induced pro-angiogenesis of hepatocellular carcinoma cells partly through regulating MKK6/p38 signaling pathway

Silymarin Inhibits Cervical Cancer Cell Through an Increase of Phosphatase and Tensin Homolog

Exploring the anti-cancer and Antimetastatic effect of Silymarin Against Lung Cancer.

Sirolimus inhibits cell proliferation and downregulates mTOR and HIF-1α expression in human hepatic carcinoma HepG2 cells

Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells

In vitro and in vivo anti-cancer activity of silymarin on oral cancer

Evaluating the Effects of Silymarin on Expressing SBDSP1 and CASC11 Genes in HCT116 Colon Cancer Cells

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells